Familial hypocalciuric hypercalcemia: Difference between revisions
| Line 14: | Line 14: | ||
Three genetically heterogeneous variants are reported so far for familial hypocalciuric hypercalcemia. | Three genetically heterogeneous variants are reported so far for familial hypocalciuric hypercalcemia. | ||
Type 1 - due to loss-of-functional mutations of the calcium-sensing receptor (encoded by CASR). Type 2 - unknown cause. | Type 1 - due to loss-of-functional mutations of the calcium-sensing receptor (encoded by CASR). Type 2 - unknown cause. | ||
Type 3 - associated with adaptor-related protein complex 2, sigma 1 subunit (AP2S1) mutations, which alter calcium-sensing receptor endocytosis | Type 3 - associated with adaptor-related protein complex 2, sigma 1 subunit (AP2S1) mutations, which alter calcium-sensing receptor endocytosis | ||
==[[Familial hypocalciuric hypercalcemia pathophysiology|Pathophysiology]]== | ==[[Familial hypocalciuric hypercalcemia pathophysiology|Pathophysiology]]== | ||
The pathophysiology of [Familial hypocalciuric hypercalcemia] is due to an inactivating missense mutation in the calcium sensing receptor (CaSR) | The pathophysiology of [Familial hypocalciuric hypercalcemia] is due to an inactivating missense mutation in the calcium sensing receptor (CaSR) located on the short arm of the chromosome 3 (FBHH3q). The mutation of CaSR is associated with two inherited conditions FBHH and neonatal hyperparathyroidism. CaSR is a plasma membrane G protein coupled receptor which is expressed on the chief cells of the parathyroid glands and the cells lining the renal tubules. CasR has the ability to sense any changes in the circulating calcium concentrated and send this information through the signaling pathway to the Parathyroid gland that modifies the PTH secretion. | ||
==[[Familial hypocalciuric hypercalcemia causes|Causes]]== | ==[[Familial hypocalciuric hypercalcemia causes|Causes]]== | ||
| Line 25: | Line 25: | ||
Parathyroid-related | Parathyroid-related | ||
Hyperparathyroidism | Hyperparathyroidism | ||
Primary hyperparathyroidism | Primary hyperparathyroidism | ||
Secondary hyperparathyroidism | Secondary hyperparathyroidism | ||
Tertiary hyperparathyroidism | Tertiary hyperparathyroidism | ||
Familial hypocalciuric hypercalcemia | Familial hypocalciuric hypercalcemia | ||
Non-parathyroid related | Non-parathyroid related | ||
Malignancy | Malignancy | ||
Humoral hypercalcemia of malignancy | Humoral hypercalcemia of malignancy | ||
Osteolytic tumors | Osteolytic tumors | ||
Production of calcitriol by tumors | Production of calcitriol by tumors | ||
Ectopic parathyroid hormone production | Ectopic parathyroid hormone production | ||
Medication-induced | Medication-induced | ||
Thiazide diuretics | Thiazide diuretics | ||
Lithium | Lithium | ||
Nutritional | Nutritional | ||
Milk-alkali syndrome | Milk-alkali syndrome | ||
Vitamin D toxicity | Vitamin D toxicity | ||
Granulomatous disease | Granulomatous disease | ||
Sarcoidosis | Sarcoidosis | ||
Surgical | Surgical | ||
Immobilization | Immobilization | ||
| Line 63: | Line 84: | ||
==Case Studies== | ==Case Studies== | ||
[[Familial hypocalciuric hypercalcemia case study one|Case #1]] | [[Familial hypocalciuric hypercalcemia case study one|Case #1]] | ||
<references /> | |||
Revision as of 15:18, 15 September 2017
|
Familial hypocalciuric hypercalcemia Microchapters |
|
Differentiating Familial Hypocalciuric Hypercalcemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Familial hypocalciuric hypercalcemia On the Web |
|
American Roentgen Ray Society Images of Familial hypocalciuric hypercalcemia |
|
Risk calculators and risk factors for Familial hypocalciuric hypercalcemia |
For patient information, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ajay Gade MD[2]]
Synonyms and keywords:
Overview
Historical Perspective
Classification
Three genetically heterogeneous variants are reported so far for familial hypocalciuric hypercalcemia. Type 1 - due to loss-of-functional mutations of the calcium-sensing receptor (encoded by CASR). Type 2 - unknown cause. Type 3 - associated with adaptor-related protein complex 2, sigma 1 subunit (AP2S1) mutations, which alter calcium-sensing receptor endocytosis
Pathophysiology
The pathophysiology of [Familial hypocalciuric hypercalcemia] is due to an inactivating missense mutation in the calcium sensing receptor (CaSR) located on the short arm of the chromosome 3 (FBHH3q). The mutation of CaSR is associated with two inherited conditions FBHH and neonatal hyperparathyroidism. CaSR is a plasma membrane G protein coupled receptor which is expressed on the chief cells of the parathyroid glands and the cells lining the renal tubules. CasR has the ability to sense any changes in the circulating calcium concentrated and send this information through the signaling pathway to the Parathyroid gland that modifies the PTH secretion.
Causes
Differentiating Xyz from other Diseases
Familial hypocalciuric hypercalcemia should be differentiated from other causes of hypercalcemia. Causes of hypercalcemia include:
Parathyroid-related
Hyperparathyroidism
Primary hyperparathyroidism
Secondary hyperparathyroidism
Tertiary hyperparathyroidism
Familial hypocalciuric hypercalcemia
Non-parathyroid related
Malignancy
Humoral hypercalcemia of malignancy
Osteolytic tumors
Production of calcitriol by tumors
Ectopic parathyroid hormone production
Medication-induced
Thiazide diuretics
Lithium
Nutritional
Milk-alkali syndrome
Vitamin D toxicity
Granulomatous disease
Sarcoidosis
Surgical
Immobilization
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Electrocardiogram | Laboratory Findings | X-Ray Findings | Echocardiography and Ultrasound | CT-Scan Findings | MRI Findings | Other Diagnostic Studies | Other Imaging Findings
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies